AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05275218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of the KDIGO bundle)
Description: Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)
Study NCT05335083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: A positive CPAP intervention
Study NCT05208983 — intervention group
Intervention type: BIOLOGICAL
Intervention: mRNA Vaccines or Viral vector-based vaccines for COVID
Description: Participants receiving an approved COVID vaccine
Study NCT05242588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005
Description: 30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Study NCT05242588 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Study NCT04209504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound guided evaluation of diaphragm ipsilateral to the block side.
Study NCT04209504 — intervention group
Intervention type: DRUG
Intervention: Ropivacaine
Description: Local anesthetic (numbing drug)
Study NCT04209504 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine
Description: Local anesthetic (numbing drug)
Study NCT04209504 — intervention group
Intervention type: DEVICE
Intervention: MediPines AGM100 Advanced Respiratory Monitoring System
Description: Non-invasive respiratory monitor to measure oxygenation and ventilation parameters
Study NCT04612049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality visuo-motor skill assessment
Description: Visuo-motor skill assessment in an immersive 3D virtual environment using a head-mounted display.
Study NCT06304311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine Obstetrics care & Lamaze breathing techniques and backside massage
Description: Lamaze breathing techniques Five breathing patterns were introduced namely- cleansing breathing for relaxation, slow-paced breathing, modified-paced breathing and patterned- paced breathing. These patterns were used during and following contractions. Gentle pushing, and breath-hold during pushing were instructed during the second stage of labor which encouraged descent of the baby.~Backside massage during 2nd stage of labor by the trained massage therapist.
Study NCT06304311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Obstetrics care & Lamaze breathing techniques and backside massage
Description: Lamaze breathing techniques Five breathing patterns were introduced namely- cleansing breathing for relaxation, slow-paced breathing, modified-paced breathing and patterned- paced breathing. These patterns were used during and following contractions. Gentle pushing, and breath-hold during pushing were instructed during the second stage of labor which encouraged descent of the baby.~Backside massage during 2nd stage of labor by the trained massage therapist.
Study NCT04679883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% GLH8NDE
Description: 5% GLH8NDE as eye drops
Study NCT04679883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as eye drops
Study NCT04679883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as eye drops
Study NCT05552690 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood draw
Description: 10 ml of blood will be draw to genetic analysis (sequencing)
Study NCT04962893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 VLP Vaccine-Wuhan
Description: Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus
Study NCT04962893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 VLP Vaccine-Alpha (British) variant
Description: Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus
Study NCT04962893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant
Description: Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the Wuhan or Alpha variants
Study NCT06234137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
Study NCT06234137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=6 min/mL iv 3-weekly
Study NCT06234137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: 8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
Study NCT06234137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400mg orally daily
Study NCT06570681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Video call assisted assessment of acute stroke
Description: If the patient is eligible for study inclusion, eight symptoms from the study protocol are evaluated and registered in the Prehospital Patient Journal (PPJ) on the amPHITM Prehospital Health Care Record (Amphi Systems, Hasserisvej 125, 9000 Aalborg, Denmark), on a tablet mounted in each EMT vehicle. Afterwards, the EMS personnel will contact the on-call neurologist and if the vehicle is in the intervention arm a live video stream is initiated. The on-call neurologist then examines the patient via via the video-call and triages the patient.
Study NCT06372041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Alternating Current Stimulation
Description: tACS will be performed by using a Conformite Europeenne (CE) marked stimulator device (Starstim ®, Neuroelectrics, Barcelona, Spain). By applying alternating current at the gamma frequency band (range 30-80), known to be associated to motor performance, tACS can entrain or synchronize neural oscillations in the targeted brain regions. By modulating cortical excitability of the cerebellum, a region strongly involved in motor learning and coordination, tACS is expected to influence the strength and coordination of motor responses elicited during the training. tACS will be delivered through two saline-soaked surface sponge electrodes (dimension: 25cm2 each), one placed over F3 (left frontal region) and the other over the right cerebellar hemisphere. The intensity will be set to 1mA, and this value will be gradually reached with a ramping-up phase of 30 secs. The frequency of the stimulation will match the IGF identified during the EEG recording performed at rest.
Study NCT05539391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data patient
Description: Medical History and characteristic of patient
Study NCT05539391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data patient
Description: Medical History and characteristic of patient
Study NCT05539391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical examination
Description: Arterial pressure, arterial oxygen saturation, heart rate
Study NCT05539391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical examination
Description: Arterial pressure, arterial oxygen saturation, heart rate
Study NCT06372041 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Alternating Current Stimulation
Description: tACS will be performed by using a Conformite Europeenne (CE) marked stimulator device (Starstim ®, Neuroelectrics, Barcelona, Spain). By applying alternating current at the gamma frequency band (range 30-80), known to be associated to motor performance, tACS can entrain or synchronize neural oscillations in the targeted brain regions. By modulating cortical excitability of the cerebellum, a region strongly involved in motor learning and coordination, tACS is expected to influence the strength and coordination of motor responses elicited during the training. tACS will be delivered through two saline-soaked surface sponge electrodes (dimension: 25cm2 each), one placed over F3 (left frontal region) and the other over the right cerebellar hemisphere. The intensity will be set to 1mA, and this value will be gradually reached with a ramping-up phase of 30 secs. The frequency of the stimulation will match the IGF identified during the EEG recording performed at rest.
Study NCT06636331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Suprainguinal Fascia Iliaca Compartment Block
Description: Using PCRA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
Study NCT06636331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Epidural
Description: Using PCEA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
Study NCT04732221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: MK-5475 (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation
Study NCT05539391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid sequence intubation (RSI) : Rocuronium /Bag-mask ventilation /GEB
Description: Rapid sequence intubation (RSI) will be performed with use of rocuronium as paralytic agent (1.2 mg/ kg). Bag-mask ventilation between induction and laryngoscopy will be performed. The GEB will be systematically used at the first attempt to facilitate intubation.
Study NCT05539391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid sequence intubation (RSI) : Recommendations for emergency intubation
Description: Rapid sequence intubation (RSI) using succinylcholine as a paralytic agent (1 mg/kg), no systematic bag-mask ventilation between induction and laryngoscopy, use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.
Study NCT06486441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy
Description: Administered intravenously
Study NCT06486441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Administered intravenously
Study NCT06486441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously
Study NCT05602597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Study participants will be administered 200 mg itraconazole by mouth twice daily after the pharmacokinetic blood draw on Day 3 and once daily on Days 4 to 10, inclusive.
Study NCT05602597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg
Description: Study participants will be administered 400 mg fluconazole by mouth daily on Day 3 after the pharmacokinetic blood draw, and 200 mg fluconazole by mouth daily on Days 4 to 10, inclusive.
Study NCT05602597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg
Description: Study participants will be administered 600 mg rifampin by mouth daily starting on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 11, inclusive.
Study NCT05602597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Description: Study participants will be administered 40 mg rabeprazole by mouth daily on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 9, inclusive.
Study NCT04732221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-5475
Description: Placebo administered as dry powder inhalation
Study NCT06024005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Solifenacin 5mg
Description: Oral solifenacin (Kinzy 5mg) use once a day for 6 weeks
Study NCT04855747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: REL-1017 tablet
Study NCT04855747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT06024005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)
Description: Application of TTNS twice a week for 6 weeks, with each session for 30 minutes
Study NCT04770272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 840 MG in 14 ML Injection
Description: 840 mg Day 1 for two weeks
Study NCT04770272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 MG in 20 ML Injection
Description: 1200 mg Day 1 every 3 weeks for 8 cycles
Study NCT04770272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab 1200 MG in 20 ML Injection
Description: 1200 mg Day 1 every 3 weeks for 8 cycles
Study NCT06514261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT06514261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06514261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT04770272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles
Study NCT06514261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal Swab
Description: Undergo buccal swab
Study NCT06514261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat
Description: Given PO
Study NCT06514261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT06085807 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Groups will receive a survey to assess attitudes about diagnosis, treatment, and genetic testing in ADPKD.
Study NCT05586763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)
Description: Each patient with vertigo symptoms will be registered in vertigo list after written consent taken. The ED doctor will take one paper from the vertigo list box and will write the case there including patient ID, date, age and symptoms. Assessment (VAS \& EEV) will be done in the pre- medication 0 min, and at 60 mins posts anti-vertigo medication. The medication will be provided blindly through the pharmacy. Any possible medication side effect and any possible further work up done for patient will be involved in each paper as ED doctor will put a tick near each point. Score will be written in papers as per patient evaluation of their symptoms grade from 1-10. The need for rescue medication ( betahisten or ondansetron ) will be recorded in the paper or is need eply manuver. Principle investigator in each centre will be responsible to collect the papers for analysis by end of each weeks.
Study NCT05773898 — intervention group
Intervention type: OTHER
Intervention: other
Description: The interviewers will collect data from relatives using questionnaires and evaluation grids based on an identification form, a Life Trajectory questionnaire, an anthropological evaluation grid, a retrospective psychiatric diagnosis questionnaire (SCID), a socio-demographic questionnaire, a questionnaire on suicide risks and a questionnaire on emotional state.
Study NCT04770272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles
Study NCT04770272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m² IV weekly x 12 cycles
Study NCT04770272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m² IV weekly x 12 cycles
Study NCT04770272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2, day 1 for 4 cycles (12 weeks)
Study NCT04770272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90 mg/m2, day 1 for 4 cycles (12 weeks)
Study NCT04770272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, day 1 for 4 cycles (12 weeks)
Study NCT04770272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, day 1 for 4 cycles (12 weeks)
Study NCT06638307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN2312
Description: MEN2312 administered as oral tablets.
Study NCT06638307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Elacestrant administered as oral tablets.
Study NCT04675710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT04675710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO
Study NCT04675710 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT04675710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04675710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04675710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT04770272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy Arm A
Description: 1st Biopsy two weeks after Baseline visit. 2nd Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 3rd Biopsy with tumor size greater 10 mm in diameter.
Study NCT04770272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy Arm B
Description: 1st Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 2nd Biopsy with tumor size greater 10mm in diameter.
Study NCT04770272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: After completion of 27-28 weeks (Arm B) or 29-30 weeks (Arm A) of neoadjuvant treatment, surgery is planned for all patients.
Study NCT04770272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: After completion of 27-28 weeks (Arm B) or 29-30 weeks (Arm A) of neoadjuvant treatment, surgery is planned for all patients.
Study NCT04819425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic Adhesive Strips
Description: Securement of Endotracheal tube with Elastic Adhesive Strips
Study NCT04819425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lace in A Protective Sheath
Description: Securement of Endotracheal tube with Lace in A Protective Sheath
Study NCT05045755 — intervention group
Intervention type: BIOLOGICAL
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
Description: The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
Study NCT05174572 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: IMR
Description: Patients undergoing coronary sinus reducer implantation (Reducer) undergo evaluation of the index of microcirculatory resistance (IMR) at the time of implantation, and at 4 months follow-up.
Study NCT03698162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo STAR DCE-MRI
Study NCT03698162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Bevacizumab will be give to participants who have recurrent high-grade glioma as part of standard of care.
Study NCT05120843 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Care coordination and motivational interviewing
Description: Interventionist will engage participants in care planning, health education, health care navigation, screening for unmet health needs or social needs, and motivational interviewing. The final intervention is expected to be six months in duration. However during this single-arm open testing phase, some participants may receive only key components of the intervention in order to assess feasibility, reach, adoption, and fidelity of those components.
Study NCT05852600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and Adolescents Talking about Healthy Sexuality (PATHS)
Description: PATHS is an intervention delivered to parents of AMSM that aims to increase parent communication about sexuality and HIV, as well as other parent behaviors supportive of sexual risk reduction. PATHS can all be accessed online, is self-paced, and typically takes parents 40-60 minutes to complete. The toolkit is comprised of 7 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. One month later parents complete a refresher module that queries them about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact.